Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients
This retrospective study is to evaluate the efficacy and safety of daptomycin (DAP) intermittent doses and the effectiveness of DAP loading dose in renal failure patients received DAP intermittent doses. One hundred and ninety-seven patients received DAP for at least 3 days from 2014 to 2017. Clinic...
Gespeichert in:
| Veröffentlicht in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2020-03, Vol.26 (3), p.215-224 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 224 |
|---|---|
| container_issue | 3 |
| container_start_page | 215 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 26 |
| creator | Kato, Hideo Hagihara, Mao Shibata, Yuichi Asai, Nobuhiro Koizumi, Yusuke Watarai, Masaya Yamagishi, Yuka Mikamo, Hiroshige |
| description | This retrospective study is to evaluate the efficacy and safety of daptomycin (DAP) intermittent doses and the effectiveness of DAP loading dose in renal failure patients received DAP intermittent doses.
One hundred and ninety-seven patients received DAP for at least 3 days from 2014 to 2017. Clinical and microbiological outcomes and the safety were assessed.
A total of 183 patients (93, 60 and 30 patients received DAP daily dose, every 48 h dose and thrice per week dose) were included. DAP intermittent doses, such as every 48 h dose (28.3%) and thrice per week dose (30.0%), showed significantly higher mortality rates than that of DAP daily dose (6.5%) (p = 0.0320). Especially for bacteremia patients, significantly higher mortality was admitted, compared with patients received DAP daily doses (p = 0.0160). Moreover, patients received DAP intermittent doses were admitted slower improvements of their inflammation after DAP therapy started, compared with patients received daily dose. Additionally, DAP loading dose for renal failure patients decreased their mortality and improved patients' inflammation early. Especially for patients received DAP thrice per week dose, they showed significantly lower mortality than patients received non-loading dose (p = 0.0306). Additionally, these clinical enhancements of DAP therapy with loading dose were admitted without any enhancements of its adverse effect risks, except alkaline phosphatase elevation, compared with non-loading dose.
In conclusion, DAP intermittent doses showed poor clinical outcomes, compared with daily dose. Then, DAP loading dose would be better clinical option for patients received DAP intermittent doses. |
| doi_str_mv | 10.1016/j.jiac.2019.09.004 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_webof</sourceid><recordid>TN_cdi_pubmed_primary_31575501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X19302764</els_id><sourcerecordid>31575501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-aa1e4d213f7611d276997e4c9f41d95ab89fb2814a7a3d9a88989c09fe55c823</originalsourceid><addsrcrecordid>eNqNkctqHDEQRUWIiR07P5BF0D70RNWPkQTZhMF5gCFgvPBOaKRSoqFHaiS1Tf9DPjrqjONlCBRUgc4pqCtC3gLbAIPth8Pm4LXZtAzkhtVi_QtyAX3HG84Fe1nnroema-H-nLzO-cAY8EGIV-S8g4EPA4ML8usWS4p5QlP8A9JcZrvQGKgZffBGjxSdq90sVAdLs3ZYFupiolZPJR4X4wP1oWA6-lIwFGpjxkwffflJK7X2OBc6Rm19-PHntfI0Yai7nfbjnJBOuvjq5ity5vSY8c1TvyR3n6_vdl-bm-9fvu0-3TSmE6w0WgP2toXO8S2AbflWSo69ka4HKwe9F9LtWwG95rqzUgshhTRMOhwGI9rukrSntaZenhM6NSV_1GlRwNSarDqoNVm1JqtYLdZX6d1Jmub9Ee2z8jfKCrw_AY-4jy6bepHBZ4wxNkAPK7qOlRb_T-98qQnFsItzKFX9eFKxRvTgMakn3fpUv1HZ6P91yG8Nwq6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients</title><source>MEDLINE</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Alma/SFX Local Collection</source><creator>Kato, Hideo ; Hagihara, Mao ; Shibata, Yuichi ; Asai, Nobuhiro ; Koizumi, Yusuke ; Watarai, Masaya ; Yamagishi, Yuka ; Mikamo, Hiroshige</creator><creatorcontrib>Kato, Hideo ; Hagihara, Mao ; Shibata, Yuichi ; Asai, Nobuhiro ; Koizumi, Yusuke ; Watarai, Masaya ; Yamagishi, Yuka ; Mikamo, Hiroshige</creatorcontrib><description>This retrospective study is to evaluate the efficacy and safety of daptomycin (DAP) intermittent doses and the effectiveness of DAP loading dose in renal failure patients received DAP intermittent doses.
One hundred and ninety-seven patients received DAP for at least 3 days from 2014 to 2017. Clinical and microbiological outcomes and the safety were assessed.
A total of 183 patients (93, 60 and 30 patients received DAP daily dose, every 48 h dose and thrice per week dose) were included. DAP intermittent doses, such as every 48 h dose (28.3%) and thrice per week dose (30.0%), showed significantly higher mortality rates than that of DAP daily dose (6.5%) (p = 0.0320). Especially for bacteremia patients, significantly higher mortality was admitted, compared with patients received DAP daily doses (p = 0.0160). Moreover, patients received DAP intermittent doses were admitted slower improvements of their inflammation after DAP therapy started, compared with patients received daily dose. Additionally, DAP loading dose for renal failure patients decreased their mortality and improved patients' inflammation early. Especially for patients received DAP thrice per week dose, they showed significantly lower mortality than patients received non-loading dose (p = 0.0306). Additionally, these clinical enhancements of DAP therapy with loading dose were admitted without any enhancements of its adverse effect risks, except alkaline phosphatase elevation, compared with non-loading dose.
In conclusion, DAP intermittent doses showed poor clinical outcomes, compared with daily dose. Then, DAP loading dose would be better clinical option for patients received DAP intermittent doses.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2019.09.004</identifier><identifier>PMID: 31575501</identifier><language>eng</language><publisher>AMSTERDAM: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Bacteremia - complications ; Bacteremia - drug therapy ; Bacteremia - epidemiology ; Bacteremia - mortality ; Daptomycin ; Daptomycin - administration & dosage ; Daptomycin - adverse effects ; Daptomycin - therapeutic use ; Dialysis patient ; Female ; Humans ; Infectious Diseases ; Intermittent dose ; Life Sciences & Biomedicine ; Loading dose ; Male ; Middle Aged ; Pharmacology & Pharmacy ; Renal failure patient ; Renal Insufficiency - complications ; Renal Insufficiency - epidemiology ; Retrospective Studies ; Science & Technology ; Soft Tissue Infections - complications ; Soft Tissue Infections - drug therapy ; Soft Tissue Infections - epidemiology ; Soft Tissue Infections - mortality ; Treatment Outcome ; Young Adult</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-03, Vol.26 (3), p.215-224</ispartof><rights>2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><rights>Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000514175500005</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c380t-aa1e4d213f7611d276997e4c9f41d95ab89fb2814a7a3d9a88989c09fe55c823</citedby><cites>FETCH-LOGICAL-c380t-aa1e4d213f7611d276997e4c9f41d95ab89fb2814a7a3d9a88989c09fe55c823</cites><orcidid>0000-0002-5732-209X ; 0000-0001-9369-8767</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934,28257</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31575501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kato, Hideo</creatorcontrib><creatorcontrib>Hagihara, Mao</creatorcontrib><creatorcontrib>Shibata, Yuichi</creatorcontrib><creatorcontrib>Asai, Nobuhiro</creatorcontrib><creatorcontrib>Koizumi, Yusuke</creatorcontrib><creatorcontrib>Watarai, Masaya</creatorcontrib><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><title>Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J INFECT CHEMOTHER</addtitle><addtitle>J Infect Chemother</addtitle><description>This retrospective study is to evaluate the efficacy and safety of daptomycin (DAP) intermittent doses and the effectiveness of DAP loading dose in renal failure patients received DAP intermittent doses.
One hundred and ninety-seven patients received DAP for at least 3 days from 2014 to 2017. Clinical and microbiological outcomes and the safety were assessed.
A total of 183 patients (93, 60 and 30 patients received DAP daily dose, every 48 h dose and thrice per week dose) were included. DAP intermittent doses, such as every 48 h dose (28.3%) and thrice per week dose (30.0%), showed significantly higher mortality rates than that of DAP daily dose (6.5%) (p = 0.0320). Especially for bacteremia patients, significantly higher mortality was admitted, compared with patients received DAP daily doses (p = 0.0160). Moreover, patients received DAP intermittent doses were admitted slower improvements of their inflammation after DAP therapy started, compared with patients received daily dose. Additionally, DAP loading dose for renal failure patients decreased their mortality and improved patients' inflammation early. Especially for patients received DAP thrice per week dose, they showed significantly lower mortality than patients received non-loading dose (p = 0.0306). Additionally, these clinical enhancements of DAP therapy with loading dose were admitted without any enhancements of its adverse effect risks, except alkaline phosphatase elevation, compared with non-loading dose.
In conclusion, DAP intermittent doses showed poor clinical outcomes, compared with daily dose. Then, DAP loading dose would be better clinical option for patients received DAP intermittent doses.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteremia - complications</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - epidemiology</subject><subject>Bacteremia - mortality</subject><subject>Daptomycin</subject><subject>Daptomycin - administration & dosage</subject><subject>Daptomycin - adverse effects</subject><subject>Daptomycin - therapeutic use</subject><subject>Dialysis patient</subject><subject>Female</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Intermittent dose</subject><subject>Life Sciences & Biomedicine</subject><subject>Loading dose</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pharmacology & Pharmacy</subject><subject>Renal failure patient</subject><subject>Renal Insufficiency - complications</subject><subject>Renal Insufficiency - epidemiology</subject><subject>Retrospective Studies</subject><subject>Science & Technology</subject><subject>Soft Tissue Infections - complications</subject><subject>Soft Tissue Infections - drug therapy</subject><subject>Soft Tissue Infections - epidemiology</subject><subject>Soft Tissue Infections - mortality</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkctqHDEQRUWIiR07P5BF0D70RNWPkQTZhMF5gCFgvPBOaKRSoqFHaiS1Tf9DPjrqjONlCBRUgc4pqCtC3gLbAIPth8Pm4LXZtAzkhtVi_QtyAX3HG84Fe1nnroema-H-nLzO-cAY8EGIV-S8g4EPA4ML8usWS4p5QlP8A9JcZrvQGKgZffBGjxSdq90sVAdLs3ZYFupiolZPJR4X4wP1oWA6-lIwFGpjxkwffflJK7X2OBc6Rm19-PHntfI0Yai7nfbjnJBOuvjq5ity5vSY8c1TvyR3n6_vdl-bm-9fvu0-3TSmE6w0WgP2toXO8S2AbflWSo69ka4HKwe9F9LtWwG95rqzUgshhTRMOhwGI9rukrSntaZenhM6NSV_1GlRwNSarDqoNVm1JqtYLdZX6d1Jmub9Ee2z8jfKCrw_AY-4jy6bepHBZ4wxNkAPK7qOlRb_T-98qQnFsItzKFX9eFKxRvTgMakn3fpUv1HZ6P91yG8Nwq6Y</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Kato, Hideo</creator><creator>Hagihara, Mao</creator><creator>Shibata, Yuichi</creator><creator>Asai, Nobuhiro</creator><creator>Koizumi, Yusuke</creator><creator>Watarai, Masaya</creator><creator>Yamagishi, Yuka</creator><creator>Mikamo, Hiroshige</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-5732-209X</orcidid><orcidid>https://orcid.org/0000-0001-9369-8767</orcidid></search><sort><creationdate>202003</creationdate><title>Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients</title><author>Kato, Hideo ; Hagihara, Mao ; Shibata, Yuichi ; Asai, Nobuhiro ; Koizumi, Yusuke ; Watarai, Masaya ; Yamagishi, Yuka ; Mikamo, Hiroshige</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-aa1e4d213f7611d276997e4c9f41d95ab89fb2814a7a3d9a88989c09fe55c823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteremia - complications</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - epidemiology</topic><topic>Bacteremia - mortality</topic><topic>Daptomycin</topic><topic>Daptomycin - administration & dosage</topic><topic>Daptomycin - adverse effects</topic><topic>Daptomycin - therapeutic use</topic><topic>Dialysis patient</topic><topic>Female</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Intermittent dose</topic><topic>Life Sciences & Biomedicine</topic><topic>Loading dose</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pharmacology & Pharmacy</topic><topic>Renal failure patient</topic><topic>Renal Insufficiency - complications</topic><topic>Renal Insufficiency - epidemiology</topic><topic>Retrospective Studies</topic><topic>Science & Technology</topic><topic>Soft Tissue Infections - complications</topic><topic>Soft Tissue Infections - drug therapy</topic><topic>Soft Tissue Infections - epidemiology</topic><topic>Soft Tissue Infections - mortality</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kato, Hideo</creatorcontrib><creatorcontrib>Hagihara, Mao</creatorcontrib><creatorcontrib>Shibata, Yuichi</creatorcontrib><creatorcontrib>Asai, Nobuhiro</creatorcontrib><creatorcontrib>Koizumi, Yusuke</creatorcontrib><creatorcontrib>Watarai, Masaya</creatorcontrib><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kato, Hideo</au><au>Hagihara, Mao</au><au>Shibata, Yuichi</au><au>Asai, Nobuhiro</au><au>Koizumi, Yusuke</au><au>Watarai, Masaya</au><au>Yamagishi, Yuka</au><au>Mikamo, Hiroshige</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><stitle>J INFECT CHEMOTHER</stitle><addtitle>J Infect Chemother</addtitle><date>2020-03</date><risdate>2020</risdate><volume>26</volume><issue>3</issue><spage>215</spage><epage>224</epage><pages>215-224</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>This retrospective study is to evaluate the efficacy and safety of daptomycin (DAP) intermittent doses and the effectiveness of DAP loading dose in renal failure patients received DAP intermittent doses.
One hundred and ninety-seven patients received DAP for at least 3 days from 2014 to 2017. Clinical and microbiological outcomes and the safety were assessed.
A total of 183 patients (93, 60 and 30 patients received DAP daily dose, every 48 h dose and thrice per week dose) were included. DAP intermittent doses, such as every 48 h dose (28.3%) and thrice per week dose (30.0%), showed significantly higher mortality rates than that of DAP daily dose (6.5%) (p = 0.0320). Especially for bacteremia patients, significantly higher mortality was admitted, compared with patients received DAP daily doses (p = 0.0160). Moreover, patients received DAP intermittent doses were admitted slower improvements of their inflammation after DAP therapy started, compared with patients received daily dose. Additionally, DAP loading dose for renal failure patients decreased their mortality and improved patients' inflammation early. Especially for patients received DAP thrice per week dose, they showed significantly lower mortality than patients received non-loading dose (p = 0.0306). Additionally, these clinical enhancements of DAP therapy with loading dose were admitted without any enhancements of its adverse effect risks, except alkaline phosphatase elevation, compared with non-loading dose.
In conclusion, DAP intermittent doses showed poor clinical outcomes, compared with daily dose. Then, DAP loading dose would be better clinical option for patients received DAP intermittent doses.</abstract><cop>AMSTERDAM</cop><pub>Elsevier Ltd</pub><pmid>31575501</pmid><doi>10.1016/j.jiac.2019.09.004</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5732-209X</orcidid><orcidid>https://orcid.org/0000-0001-9369-8767</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-03, Vol.26 (3), p.215-224 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_pubmed_primary_31575501 |
| source | MEDLINE; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Bacteremia - complications Bacteremia - drug therapy Bacteremia - epidemiology Bacteremia - mortality Daptomycin Daptomycin - administration & dosage Daptomycin - adverse effects Daptomycin - therapeutic use Dialysis patient Female Humans Infectious Diseases Intermittent dose Life Sciences & Biomedicine Loading dose Male Middle Aged Pharmacology & Pharmacy Renal failure patient Renal Insufficiency - complications Renal Insufficiency - epidemiology Retrospective Studies Science & Technology Soft Tissue Infections - complications Soft Tissue Infections - drug therapy Soft Tissue Infections - epidemiology Soft Tissue Infections - mortality Treatment Outcome Young Adult |
| title | Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T12%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20study%20on%20clinical%20efficacy%20and%20safety%20for%20daptomycin%20intermittent%20doses%20with%20or%20without%20loading%20dose%20in%20renal%20failure%20patients&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Kato,%20Hideo&rft.date=2020-03&rft.volume=26&rft.issue=3&rft.spage=215&rft.epage=224&rft.pages=215-224&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2019.09.004&rft_dat=%3Cpubmed_webof%3E31575501%3C/pubmed_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31575501&rft_els_id=S1341321X19302764&rfr_iscdi=true |